Dr. Beasley received a Ph.D. in Life Sciences from the Queensland University of Technology, Brisbane, Australia in 1999. Research in his lab currently focuses on the molecular basis of phenotypic variations between individual strains and major groups of flaviviruses, including West Nile virus and other Japanese encephalitis complex viruses, the dengue viruses, yellow fever virus, and tick-borne flaviviruses such as Powassan virus. These studies aim to facilitate development of new and improved vaccines, diagnostics and therapeutics for this important group of emerging and re-emerging arthropod-borne viruses. He serves as a member of the Executive Committee of the Sealy Center for Vaccine Development and is a formerCo-Director of UTMB's select agent BSL3 laboratories and the former Director of the Galveston National Laboratory Regulatory Compliance Core. He has been actively involved in UTMB's preparations for the conduct of regulated nonclinical studies at BSL3/4 since 2005, with an emphasis on development and use of animal models for testing and approval of new vaccines and therapeutics under the Animal Rule.